William R Hiatt
Affiliation: University of Colorado Denver
- Pathogenesis of the limb manifestations and exercise limitations in peripheral artery diseaseWilliam R Hiatt
From the Division of Cardiology, Department of Medicine W R H, E J A, CPC Clinical Research W R H, University of Colorado School of Medicine, Aurora Cardiovascular and Metabolic Diseases Drug Discovery Unit, Takeda Pharmaceuticals, San Diego, CA C J L and Department of Medicine, Harbor UCLA Center for Clinical Pharmacology, Torrance, CA E P B
Circ Res 116:1527-39. 2015....
- A validated biomarker panel to identify peripheral artery diseaseWilliam R Hiatt
University of Colorado School of Medicine, Division of Cardiology, Aurora, CO 80045, USA
Vasc Med 17:386-93. 2012..The model also performed well in subjects with no prior history of PAD. Thus, a biomarker panel may have a role for identifying PAD...
- Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery diseaseWilliam R Hiatt
University of Colorado School of Medicine, Division of Cardiology and CPC Clinical Research, Aurora, Colorado 80045, USA
J Cardiopulm Rehabil Prev 31:125-32. 2011..This trial tested the hypothesis that propionyl-L-carnitine (PLC), in combination with monitored home-based exercise training, would improve treadmill peak walking time (PWT) over exercise training alone...
- Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise trainingW Schuyler Jones
Division of Cardiology, Duke University Medical Center, Durham, NC, USA
Vasc Med 17:94-100. 2012..These somewhat unexpected findings suggest that further investigation into the mechanism of vascular responses to exercise training in PAD patients is warranted...
- The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) ProgramJudith G Regensteiner
Department of Medicine, University of Colorado School of Medicine, Denver, CO 80262, USA
Vasc Med 13:15-24. 2008....
- Association of clinical attributes and treadmill walking performance in patients with claudication due to peripheral artery diseaseEric P Brass
Harbor University of California Los Angeles UCLA Center for Clinical Pharmacology, Torrance, CA, USA
J Vasc Surg 58:396-403. 2013..This study evaluated factors suspected to be correlated with treadmill walking performance in an effort to gain insights into the pathophysiology of the impairment...
- A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudicationEric P Brass
Harbor UCLA Center for Clinical Pharmacology, Torrance, CA 90502, USA
J Vasc Surg 55:381-389.e1. 2012..K-134, a novel phosphodiesterase inhibitor, was evaluated in a phase II trial incorporating an adaptive design to assess its safety, tolerability, and effect on treadmill walking time...
- Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery diseaseJennifer L Robbins
Department of Medicine, Division of Cardiology, Duke University Medical Center, Box 3126, Durham, NC 27710, USA
J Appl Physiol (1985) 111:81-6. 2011..These findings suggest that alterations in microcirculation may contribute to functional impairment capacity in PAD...
- Angiogenesis in skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patientsBrian D Duscha
Duke University Medical Center, Division of Cardiology, Durham, NC 27710, USA
Arterioscler Thromb Vasc Biol 31:2742-8. 2011..This study tested the hypothesis that in PAD patients who undergo supervised exercise training, increases in capillary density (CD) in calf muscle take place before improvements in peak oxygen uptake (VO(2))...
- Assessment of functional status and quality of life in claudicationRyan J Mays
Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA
J Vasc Surg 53:1410-21. 2011..Although this is an important measure, it does not provide information about how patients perceive the effects of their treatments on more global measures of health-related quality of life (HRQOL)...
- Clinical outcomes using aggressive approach to anatomic screening and endovascular revascularization in a veterans affairs population with critical limb ischemiaAlap P Shah
Department of Medicine, University of Colorado Denver, Aurora, Colorado, USA
Catheter Cardiovasc Interv 74:11-9. 2009....
- L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trialNeil A Goldenberg
Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, CO 80045, USA
Vasc Med 17:145-54. 2012..145 for cilostazol/placebo (p = 0.048). QOL measures were also improved in the cilostazol/l-carnitine group. These findings support larger trials of l-carnitine in combination with cilostazol in the treatment of IC...
- A randomized trial of iloprost in patients with intermittent claudicationMark A Creager
Department of Medicine, Division of Cardiology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Vasc Med 13:5-13. 2008..039). Neither iloprost nor pentoxifylline enhanced quality of life. These results indicate that oral iloprost is not effective in improving exercise performance or quality of life in patients with PAD who have intermittent claudication...
- The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial diseaseEric P Brass
Department of Medicine, Harbor UCLA Medical Center, Torrance, California 90502, USA
J Am Coll Cardiol 48:2539-45. 2006..The current study tested the hypothesis that NM-702 improves treadmill exercise performance in peripheral arterial disease patients with claudication-limited exercise performance...
- Peripheral arterial disease rehabilitation: a reviewRita A Falcone
Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
J Cardiopulm Rehabil 23:170-5. 2003
- Skeletal muscle metabolic changes in peripheral arterial disease contribute to exercise intolerance: a point-counterpoint discussionEric P Brass
Center for Clinical Pharmacology, Department of Medicine, Harbor UCLA Medical Center, Torrance, CA, USA
Vasc Med 9:293-301. 2004..The relative contribution of these factors and their role in the pathophysiology of the exercise limitation is discussed using a point-counterpoint approach. Future directions for research conclude the discussion...
- Increased levels of apoptosis in gastrocnemius skeletal muscle in patients with peripheral arterial diseaseRobert G Mitchell
Division of Cardiology, Department of Medicine, Durham VA and Duke University Medical Center, Durham, NC 27710, USA
Vasc Med 12:285-90. 2007..53% +/- 0.96; p < 0.001). In conclusion, PAD is associated with increased levels of apoptosis in the peripheral skeletal muscle. Further study is required to ascertain whether apoptosis plays a role in decreased functional capacity...
- Peripheral arterial disease is not associated with an increased prevalence of intradialytic cramps in patients on maintenance hemodialysisEric P Brass
Department of Medicine, Harbor UCLA Medical Center, Torrance, Calif 90502, USA
Am J Nephrol 22:491-6. 2002..Peripheral arterial disease (PAD) has been suggested as a contributing factor to the development of intradialytic muscle cramps in patients on maintenance hemodialysis...
- Risk assessment in the patient with established peripheral arterial diseaseScott Haugen
Divisions of Cardiology and General Internal Medicine, Department of Medicine, University of Colorado School of Medicine, Denver, CO, USA
Vasc Med 12:343-50. 2007..Defining which patients are in the highest category of risk may direct health care providers to emphasize secondary preventive measures, and facilitate patient adherence to recommended medical therapies and smoking cessation...
- Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudicationRoger J Lewis
Department of Emergency Medicine, Harbor UCLA Medical Center, 1000 West Carson Street, Torrance, California 90509, USA
Trials 12:134. 2011..We describe the design, oversight, and implementation of an adaptive, phase II, dose-finding trial evaluating K-134 for the treatment of stable, intermittent claudication...
- Exercise training for claudicationKerry J Stewart
Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA
N Engl J Med 347:1941-51. 2002
- A systematic review and meta-analysis of propionyl-L-carnitine effects on exercise performance in patients with claudicationEric P Brass
Harbor UCLA Center for Clinical Pharmacology, Torrance, CA, USA
Vasc Med 18:3-12. 2013..In conclusion, oral PLC is associated with a statistically significant increase in PWD in patients with claudication, which may be clinically relevant...
- Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapiesEric P Brass
Harbor UCLA Center for Clinical Pharmacology, 1124 W Carson Street, Torrance, CA 90502, USA
Vasc Med 11:141-5. 2006..The current analyses provide benchmark data for ensuring that development programs are large enough to allow meaningful safety conclusions, and to assist in data and safety monitoring of these trials...
- Patterns of artery disease in 450 patients undergoing revascularization for critical limb ischemia: implications for clinical trial designCarlos A Rueda
University of Colorado Health Sciences Center, Aurora, CO 80045, USA
J Vasc Surg 47:995-9; discussion 999-1000. 2008..The pattern and distribution of arterial occlusions and stenoses in patients with critical limb ischemia presenting at two academic medical centers was described...
- Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacyWilliam R Hiatt
Department of Medicine, University of Colorado School of Medicine, Section of Vascular Medicine, and the Colorado Prevention Center, Denver, CO 80203, USA
Vasc Med 9:18-25. 2004..These data indicate that selective serotonin receptor blockade does not improve exercise tolerance or quality of life in individuals with claudication...
- Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemiaEric P Brass
Harbor UCLA Medical Center for Clinical Pharmacology, Torrance, California 90502, USA
J Vasc Surg 43:752-9. 2006..The current trial was designed to test the hypothesis that lipo-ecraprost would improve amputation-free survival in patients with CLI who had no revascularization options...
- Community walking programs for treatment of peripheral artery diseaseRyan J Mays
Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colo Center for Women s Health Research, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colo Electronic address
J Vasc Surg 58:1678-87. 2013..This review evaluated the various methods and outcomes of community walking programs for PAD...
- Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trialsJeffrey S Berger
Department of Medicine, Division of Cardiology, New York University School of Medicine, New York, NY 10016, USA
Am Heart J 162:115-24.e2. 2011..The benefit of aspirin to prevent cardiovascular events in subjects without clinical cardiovascular disease relative to the increased risk of bleeding is uncertain...
- Masterclass series in peripheral arterial disease. Antiplatelet therapy for peripheral arterial disease and claudicationWilliam R Hiatt
Department of Medicine, University of Colorado School of Medicine, Section of Vascular Medicine, Divisions of Geriatrics and Cardiology, Denver, Colorado 80203, USA
Vasc Med 11:55-60. 2006..The use of aspirin as well as more potent antiplatelet therapies such as thienopyridines holds promise for reducing atherothrombosis in this very high-risk population...
- The "parallel-cohort RCT": Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolismNeil A Goldenberg
Dept of Pediatrics, Section of Hematology Oncology Bone Marrow Transplantation and Mountain States Regional Hemophilia and Thrombosis Center, Univ of Colorado Denver and The Children s Hospital, Aurora, CO, USA
Contemp Clin Trials 31:131-3. 2010....
- Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reportingDavid P Kao
Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA
Pharmacotherapy 32:767-71. 2012..To characterize the frequency and type of cardiac events, including torsade de pointes, associated with dronedarone and its structural analog, amiodarone, outside of the clinical trial setting...
- Pharmacologic therapy for peripheral arterial disease and claudicationWilliam R Hiatt
Department of Medicine, University of Colorado School of Medicine, c o Colorado Prevention Center, 789 Sherman Street, Suite 200, Denver, CO 80203, USA
J Vasc Surg 36:1283-91. 2002....
- Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trialRobert W Schrier
Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Denver, CO 80262, USA
Nat Clin Pract Nephrol 3:428-38. 2007..Analysis of the results of 5 years of follow-up revealed a highly significant correlation of all-cause and cardiovascular mortality with left ventricular mass and severity of albuminuria...
- Clinical and demographic predictors of exercise capacity in end-stage renal diseaseKathy E Sietsema
Department of Medicine, Harbor UCLA Research and Education Institute, Torrance, CA, USA
Am J Kidney Dis 39:76-85. 2002....
- Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO modelNeil A Goldenberg
Department of Medicine, Section of Hematology Oncology, University of Colorado, Aurora, CO, USA
Blood 117:2089-92. 2011..Although numerous models can be entertained, the ARO-CRO model is uniquely structured to meet the demand for greater assurance of integrity in clinical trials and the needs of each stakeholder in the process...